Protein kinase B (PKB/Akt) is a regulator of cell survival and apoptosis. To become fully activated, PKB/Akt requires phosphorylation at two sites, threonine 308 and serine 473, in a phoshpatidylinositol (PI) 3-kinasedependent manner. The kinase responsible for phosphorylation of threonine 308 is the PI 3-kinase-dependent kinase-1 (PDK-1), whereas phosphorylation of serine 473 has been suggested to be regulated by PKB/Akt autophosphorylation in a PDK-1-dependent manner. However, the integrin-linked kinase (ILK) has also been shown to regulate phosphorylation of serine 473 in a PI 3-kinase-dependent manner. Whether ILK phosphorylates this site directly or functions as an adapter molecule has been debated. We now show by in-gel kinase assay and matrix-assisted laser desorption-ionization time-of-flight mass spectrometry that biochemically purified ILK can phosphorylate PKB/Akt directly. Co-immunoprecipitation analysis of cell extracts demonstrates that ILK can complex with PKB/Akt as well as PDK-1 and that ILK can disrupt PDK-1/PKB association. The amino acid residue serine 343 of ILK within the activation loop is required for kinase activity as well as for its interaction with PKB/Akt. Mutational analysis of ILK further shows a crucial role for arginine 211 of ILK within the phosphoinositide phospholipid binding domain in the regulation of PKB-serine 473 phosphorylation. A highly selective small molecule inhibitor of ILK activity also inhibits the ability of ILK to phosphorylate PKB/Akt in vitro and in intact cells. These data demonstrate that ILK is an important upstream kinase for the regulation of PKB/Akt.
Interaction of cells with the extracellular matrix results in the suppression of apoptosis and promotes cell cycle progression (1) (2) (3) (4) . The molecular basis for this anchorage-dependent cell growth and survival is an intensive area of study, since oncogenically transformed cells very often grow in an anchorage-independent manner. Alterations in anchorage-dependent signaling pathways are also likely to be of importance in tumor progression leading to metastasis. The integrin-linked kinase (ILK) 1 is an intracellular protein kinase that couples integrins and growth factors to downstream signaling pathways involved in the suppression of apoptosis and in promoting cell cycle progression. Cell-extracellular matrix interactions stimulate two major signaling pathways, leading to the regulation of cell cycle progression and cell survival. These are the Ras/Raf-MAP kinase pathway, and the protein kinase B/Akt (PKB/Akt) cell survival pathway (5) . ILK regulates both the cell cycle, by stimulating the expression of cyclin D1 (6, 7) and cyclin A (7) , and the activity of PKB/Akt, by stimulating the phosphorylation of PKB/Akt on serine 473 in a PI-3 kinase-dependent manner (8, 9) , a requirement for full activation of this enzyme. Overexpression of ILK suppresses anoikis by activating PKB/ Akt (10) , and ILK activity is constitutively up-regulated in tumor cells lacking expression of the PI(3,4,5)P 3 phosphatase tumor suppressor PTEN (11, 12) . Inhibition of ILK activity in such cells results in the inhibition of PKB/Akt serine 473 phosphorylation and activation (12) , inhibition of cell cycle progression, and stimulation of apoptosis (12) . Activated PKB/Akt suppresses apoptosis and anoikis by phosphorylating and inactivating proapoptotic molecules such as Bad, caspase-9, and the forkhead transcription factors.
ILK overexpression also stimulates nuclear localization of ␤-catenin and activation of the ␤-catenin-Lef-1 transcription factor, probably due to the ILK-dependent phosphorylation and inhibition of glycogen synthase kinase-3 (6, 8, 13) . These data implicate ILK as an important upstream regulator of the cell cycle and cell survival and growth pathways (5) .
Although ILK has been shown to autophosphorylate (14) and can phosphorylate a number of protein substrates, such as a peptide derived from the ␤ 1 integrin cytoplasmic domain, my-elin basic protein, PKB/Akt, and glycogen synthase kinase-3 (6, 8, 14, 15) , it has been suggested by others that ILK may not be an active kinase (9) and that the ILK-mediated regulation of PKB/ Akt serine 473 phosphorylation may be indirect (9) . This skepticism arises from the fact that there are a number of amino acid changes in the kinase catalytic domain of ILK at positions that are typically highly conserved. For instance, the highly conserved GXGXXG sequence found in subdomain I is NENHSG in ILK, and additional variations in ILK are found in the conserved residues in subdomains VIB (HRDL) and VII (DFG). On the other hand, the critical lysine residue between subdomains I and II, involved in the binding of ATP, and the APE region in subdomain VIII are highly conserved. Despite these differences, recent work by Deng et al. (16) clearly demonstrates that ILK is a bona fide functional serine-threonine protein kinase.
ThecurrentmodelforPKB/AktactivationrequiresPI3-kinasedependent phosphorylation of threonine 308 and serine 473. The kinase responsible for phosphorylation of threonine 308 has been identified as PI 3-kinase-dependent kinase-1 (PDK-1) (17) . However, the regulation of phosphorylation of the hydrophobic site serine 473 has been attributed to autophosphorylation by PKB/Akt (18) . A role for PDK-1 in the regulation of phosphorylation at this site has also been conjectured by analogy of the ability of PDK-1 to bind to a similar hydrophobic site serine residue in protein kinase C (19, 20) . PDK-1, by binding to the serine 473 site, is proposed to mask this site. A PDK-1 inhibitory factor (PIF) peptide, generated from PRK-2 (29), has been proposed to displace PDK-1 from this site, allowing for autophosphorylation to take place (18, 21) . However, there is no evidence for the existence of a physiologically relevant PIF in cells (18) .
Here we show using in-gel kinase assay and MALDI-TOF mass spectrometry, that ILK can phosphorylate PKB/Akt directly. Mutational analysis reveals a crucial role for amino acids serine 343 and arginine 211 in the activation loop and phosphoinositide phospholipid binding motif of ILK, respectively, in the regulation of phosphorylation of PKB/Akt on serine 473. Interestingly, ILK can complex with PKB/Akt and PDK-1, disrupting PDK-1/PKB interactions and promoting phosphorylation of PKB/Akt on serine 473.
EXPERIMENTAL PROCEDURES
Site-directed Mutagenesis-Mutations were introduced into V 5 /Histagged-ILK-WT pcDNA3.1 using the QuickChange site-directed mutagenesis kit (Stratagene). Mutant oligonucleotides (with the altered nucleotide(s) underlined) were used to change serine at position 343 to an alanine (S343A, 5Ј-ATGGCTGATGTCAAGTTCGCTTTCCAAT-GTCCTGGTCGC-3Ј), serine at position 343 to an aspartic acid (S343D, 5Ј-ATGGCTGATGTCAAGTTCGATTTCCAATGTCCTGGTCGC-3Ј), and arginine at position 211 to an alanine (R211A, 5Ј-GAGCTATG-GAAGGGCGCCTGGCAGGGCAATGAC-3Ј). Mutant clones were confirmed by sequencing.
Cell Culture, Transfections, and Inhibitor Treatment-The PTENpositive prostate cancer cell line DU145 and the PTEN-null prostate cancer cell line PC3 were used in this study. DU145 and PC3 cells were cultured in DMEM containing 10% FBS. All cells were passaged in 5% CO 2 at 37°C. The cells were transiently transfected with His-V 5 -tagged ILK wild-type (ILK-WT) cDNA, His-V 5 -tagged ILK kinase-dead (ILK-E359K) cDNA, His-V 5 -tagged ILK (S343A) cDNA, His-V 5 -tagged ILK (S343D) cDNA, His-V 5 -tagged ILK (R211A) cDNA, His-V 5 -tagged ILK (E359K/S343A) cDNA, His-V 5 -tagged ILK (E359K/S343D) cDNA, and His-V 5 -tagged ILK (R211A/S343D) cDNA. Transfections of DU145 cells were carried out by using 6 l of Fugene 6 reagent (Roche Molecular Biochemicals), according to the manufacturer's guidelines, and 2-3 g of cDNA. Transfection of PC3 cells were carried out by using 4 l of Lipofectin reagent (Life Technologies, Inc.), according to the manufacturer's guidelines, and using 2-3 g of cDNA. Control cells were transfected with empty vector. The ILK cDNAs were in the pc-DNA-3 plasmid. All transfections were carried out overnight, and the cells were harvested for lysis 24 -48 h later with Nonidet P-40 lysis buffer as described previously (12) .
Prior to treatment with inhibitors, DU145 and PC3 cells were serum- In vitro ILK assays were also carried out in which purified GST-PKB and GST-ILK were co-incubated in the presence of kinase reaction buffer and ATP as described previously (8) . The kinase assays were carried out in the presence or absence of KP-SD-1. Phosphorylated GST-PKB was resolved by SDS-PAGE and detected by Western blot analysis using the anti-PKB-Ser(P)-473 antibody (rabbit polyclonal; New England Biolabs). In addition, in vitro kinase assays were also carried out using Mono Q fractions containing ILK partially purified from chicken gizzard smooth muscle (16) and either the 20-kDa light chain of smooth muscle myosin II (MLC-20) as substrate and [␥- 32 P]ATP as the phosphate donor or GST-PKB-Ala-308 as substrate and ATP as phosphate donor. Phosphorylated MLC-20 was detected by SDS-PAGE and autoradiography, and phosphorylated GST-PKB was resolved by SDS-PAGE and detected by Western blot analysis using the anti-PKBSer(P)-473 antibody (rabbit polyclonal; New England Biolabs).
In-gel Kinase Assay and MALDI-TOF Mass Spectrometric AnalysisMono Q fractions (16) were mixed with 4 l of 4ϫ SDS gel sample buffer and incubated at 20°C for 2 h prior to electrophoresis. Two 10% polyacrylamide gels were prepared: one with the protein substrate GST-PKB-Ala-308 (60 g/ml) incorporated into it and one without any substrate. After electrophoresis, the gels were first washed with kinase assay buffer (50 mM Hepes, pH 7, 2 mM MgCl 2 , 2 mM MnCl 2 , 2 mM NaF, 1 mM Na 3 VO 4 , 10 mM dithiothreitol) containing 2.5% SDS and then washed with kinase buffer without SDS overnight at 4°C. The gels were then incubated with fresh kinase buffer containing 200 Ci of [␥- 32 P]ATP for 3 h at 25°C. The gels were thereafter washed extensively with 5% trichloroacetic acid and 1% sodium pyrophosphate, stained with Coommassie Blue, destained, dried, and visualized by autoradiography.
A major radioactive band with an apparent molecular mass of 59-kDa kinase was detected in the substrate-containing gel. This 59-kDa band was excised from the gel, and MALDI-TOF analysis was performed on this band after trypsin digestion by Borealis Biosciences Inc. (Toronto, Ontario, Canada).
Expression and Purification of GST-ILK and GST-PKB-GST-ILK fusion protein was expressed in insect cells using the baculovirus system. The open reading frame from an ILK cDNA was amplified using Vent polymerase (New England Biolabs), inserted into transfer vector pAcG2T (Pharmingen), and verified by ABI PRISM cycle sequencing (PerkinElmer Life Sciences). This plasmid was then co-transfected with BaculoGold DNA (Pharmingen) in Sf9 cells to produce the ILK recombinant baculovirus and then used for infection of Hi5 cells (Invitrogen). After 3 days of infection, the cells were lysed by sonication in 10 mM imidizole, 5 mM EDTA, 0.1% ␤-mercaptoethanol, 10 g/ml phenylmethylsulfonyl fluoride, and 1 mM benzamidine. ILK protein was purified from these lysates using glutathione-agarose beads.
pGEX-PKB Ala308 was expressed in BL21 Codon Plus 'PR' bacteria (Stratagene) by induction with 1 mM isopropyl-1-thio-␤-D-galactopyranoside at 37°C for 3 h. Bacteria were lysed in 20 mM Tris-HCl, pH 7.5, 10 mM EDTA, 1% Triton X-100 (wash buffer; Protein Refolding Kit, Novagen) to which was added 100 g/ml lysozyme, 50 units/ml of a broad spectrum nuclease (Benzonase, Novagen), and a protease inhibitor mixture (Roche Molecular Biochemicals). After sonication and further incubation at 4°C with stirring, the nonsolubilized fraction was collected by centrifugation at 10,000 ϫ g for 10 min. This inclusion body pellet was washed twice with wash buffer and was solubilized in 50 mM CAPS, 0.3% N-lauroylsarcosine, and protease inhibitors. Insoluble material was removed by centrifugation at 10,000 ϫ g for 10 min. The soluble inclusion body material was substantially pure GST-PKB Ala 308 protein as determined by SDS-PAGE analysis. Detergent was removed by exhaustive dialysis against phosphate-buffered saline at 4°C.
Coimmunoprecipitation Assays-DU145 cells were cultured, transfected, and harvested as described earlier. 250 g of cell lysate was precleared with 30 l of rabbit IgG (Sigma)-coated protein A-Sepharose beads (Sigma), for 4 h twice at 4°C with rotation. Lysates were then incubated overnight with 4 g of the appropriate antibody, followed by incubation with 30 l of protein A-Sepharose beads for 1 h. Beads were washed in lysis buffer five times, and proteins were resolved by SDS-PAGE and Western blotted with the appropriate antibody, as described above.
RESULTS

ILK Phosphorylates PKB/Akt on Serine 473-ILK
can interact with the cytoplasmic domains of integrin ␤ 1 and ␤ 3 subunits (14) , and its activity is stimulated by adhesion to extracellular matrix proteins (5) as well as by growth factors in a PI 3-kinasedependent manner (5) . ILK contains a phosphoinositide phospholipid binding motif (8) , and its activity is stimulated in vitro by PI(3,4,5)P 3 , the product of PI 3-kinase (8) .
ILK activity is negatively regulated by the PI(3,4,5)P 3 lipid phosphatase, PTEN (12) . When transfected into epithelial cells, wild type-ILK stimulates the phosphorylation of PKB/Akt on serine 473 in a PI 3-kinase-dependent manner (9, 12) , and kinase-deficient forms of ILK, E359K (22) , and K220A (9) behave as dominant negative forms and suppress serine 473 phosphorylation of PKB (9, 12) . Despite prior demonstration of the ability of recombinant ILK to phosphorylate PKB/Akt at serine 473 in vitro, it has been suggested that ILK may regulate this phosphorylation of PKB/Akt indirectly rather than by direct phosphorylation (9) .
To determine whether tissue-derived ILK can phosphorylate PKB/Akt directly, we took advantage of a recently described purification and kinase activity analysis scheme for the demonstration of phosphorylation of MLC-20 by ILK (16) . ILK was enriched from chicken gizzard extracts using conventional biochemical purification protocols (DEAE-Sepharose chromatography, SP-Sepharose chromatography, and Mono-Q chromatography) described by Deng et al. (16) . The Mono-Q fractions were then analyzed for PKB/Akt phosphorylation activity by an in-gel kinase assay using purified recombinant PKB/Akt as the substrate. To minimize autophosphorylation and eliminate the role of PDK-1, we used a threonine 308 mutant of PKB (T308A) as the substrate. Purified PKB (T308A) (Fig. 1A) was incorporated into a 10% polyacrylamide gel. In-gel kinase assays of Mono-Q fractions were carried out as described under "Experimental Procedures." A representative autoradiograph of one of three separate experiments is shown in Fig. 1B . A major band capable of phosphorylating PKB (T308A) was detected with a molecular mass of ϳ59 kDa in Mono-Q fractions 20 -25. Coomassie Blue staining of the gel revealed a single protein band in this location. This band was excised from the gel, digested with trypsin, and analyzed by MALDI-TOF mass spectrometry (Fig. 1C) (16) . Comparison of the measured masses of the tryptic peptides with predicted masses from the protein sequence data bases revealed a single match to ILK (Fig. 1C) (14) . Peptides 1-16 perfectly matched predicted tryptic peptides from chicken ILK (16), and together the 16 peptides accounted for 35% of the complete sequence. No sequences corresponding to any other proteins were obtained. Western blot analyses of the Mono-Q fractions 17-28 with a polyclonal anti-ILK antibody showed that ILK was present in the fractions containing PKB phosphorylatable activity (fractions 20 -25) . These results confirm that ILK can phosphorylate PKB/Akt.
The second minor peak of activity in fractions 26 and 27 migrating with relative molecular masses of 100 and 85 kDa has not been identified yet.
We also decided to determine whether the Mono-Q fractions could phosphorylate PKB (T308A) on serine 473 in solution. Aliquots of Mono-Q fractions 18 -27 were incubated with either PKB (T308A) or MLC-20. Kinase assays were carried out as described under "Experimental Procedures" using either [␥-
32 P]ATP for phosphorylation of MLC-20 or cold ATP for detection of PKB (T308A) phosphorylation on serine 473 using FIG. 1. Biochemical purification, in-gel kinase assay, and MALDI-TOF mass spectrometry identify ILK as a PKB kinase. A, Coomassie Blue stain and Western blot analysis of purified GST-PKBAla-308 which was used in the in-gel kinase assay to minimize autophosphorylation and eliminate the role of PDK-1. B, Mono Q fractions were electrophoresed through a polyacrylamide gel that had 60 g/ml of highly purified GST-PKB Ala-308 incorporated throughout. After electrophoresis, an in-gel kinase assay was performed to identify constituents of the Mono Q fractions able to phosphorylate the GST-PKB Ala-308 substrate. A 59-kDa protein was identified. Western blotting of the Mono Q fractions with anti-ILK antibody showed that the same fractions that contained a 59-kDa protein with PKB phosphorylation activity also contained ILK. C, MALDI-TOF MS was performed on the tryptic digest of the 59-kDa band. Comparison of the masses of the tryptic peptides with predicted masses from protein sequence data base revealed a match to integrin-linked kinase (ILK).
an anti-PKB-Ser(P)-473 antibody. As shown in Fig. 2A , a peak of activity is detected in fractions 20 -25 for phosphorylation of both MLC-20 and PKB (T308A). Furthermore, the kinase activity in fraction 24 was substantially inhibited in the presence of a highly selective small molecule ILK inhibitor, KP-SD-1 ( Table I) , demonstrating that the kinase activity in the fractions responsible for phosphorylating PKB on serine 473 is ILK.
We next incubated recombinant GST-ILK expressed in insect cells with E. coli expressed recombinant PKB/Akt and carried out in vitro kinase assays. The reaction products were probed with an anti-PKB-Ser(P)-473 antibody to detect phosphorylation of PKB at serine 473. As shown in Fig. 2B , very little phosphorylation of PKB/Akt was detected in the absence of GST-ILK. The addition of GST-ILK resulted in substantial stimulation of PKB/Akt phosphorylation at serine 473, and this phosphorylation was almost completely inhibited by the ILKselective inhibitor, KP-SD-1 ( Table I) . As a control, the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD98059 had no significant effect on the ability of ILK to phosphorylate PKB/Akt on serine 473. These data support the in-gel kinase assay shown in Fig. 1B. (i.e. identification of ILK as a PKB/Akt kinase stimulating phosphorylation of PKB/Akt on serine 473).
Mutational Analysis of ILK: Identification of Critical Amino Acid Residues for Kinase Activity and Regulation of PKB/Akt
Phosphorylation in Vivo-In order to gain further insight into the catalytic function of ILK and the role of the PI(3,4,5)P 3 -binding motif in the regulation of PKB/Akt phosphorylation, we mutated specific amino acid residues within the PI(3,4,5)P 3 -binding motif and the kinase domain that have been implicated in these functions. The residues mutated are shown in Fig. 3 . Arginine 211 (R211) within the WKGRW motif has previously been shown to be important in binding phosphoinositide phospholipids in pleckstrin homology domains (23) . Glutamic acid 359 (E359) within subdomain VIII is invariant in protein kinases and has previously been shown to be essential for kinase catalytic function (24) . We have previously shown that mutation of glutamic acid 359 to lysine (E359K) results in a kinasedeficient ILK that functions as a dominant negative (22) . Serine 343 (S343) is in the hydrophobic motif FSF within the activation loop of the kinase domain and has previously been suggested to be the target of autophosphorylation (9) . Mutation of serine 343 to alanine (S343A) resulted in the inability of ILK to stimulate phosphorylation of PKB/Akt in COS cells (9) .
We mutated these three residues as follows: R211A, S343A, S343D, and E359K. In addition, we created the following double mutants: R211A/S343D and E359K/S343D. We initially characterized some of these mutants for kinase activity in vitro. Wild-type ILK and ILK mutants were expressed as GST fusion proteins in insect cells, purified, and assayed for kinase activity using a peptide derived from the S6 kinase substrate, as described under "Experimental Procedures" and in Table II . The results for wild-type ILK and the ILK mutants S343A and E359K are shown in Fig. 4 . The mutation of Glu 359 to Lys results in inhibition of kinase activity, but this mutant retains at least 20% of its activity. However this mutant functions as a potent dominant negative (10, 12, 22, 25) . On the other hand, mutation of the activation loop serine, S343A, completely abolishes kinase activity (Fig. 4) , whereas substitution with aspartic acid, S343D, does not alter kinase activity (data not shown). These data demonstrate a crucial role for Ser-343 in the catalytic function of ILK toward exogenous substrates.
We next assessed the ability of these mutants to regulate PKB/Akt phosphorylation on serine 473 in cells. In order to do this, we used PTEN-positive and PTEN-negative human prostate carcinoma cell lines, DU145 and PC3, respectively. We have extensively characterized these cell lines previously and B, in vitro ILK kinase activity was assayed using recombinant GST-ILK and recombinant GST-PKB as substrate and cold ATP as phosphate group donor. Phosphorylation of PKB at serine 473, detected by Western blotting, was significantly inhibited in the presence of the ILK inhibitor, KP-SD-1. The presence of the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD98059 had no effect on serine 473 phosphorylation of PKB. 
a CK II, casein kinase II; DNA-PK, DNA-dependent protein kinase; ERK1, extracellular signal regulated kinase 1; GSK-3␤, glycogen synthase kinase 3␤; MEK, mitogen-activated protein kinase kinase; PKA, protein kinase A; PAK, p21-activated protein kinase; PKC, protein kinase C; CDK1, cyclin-dependent kinase 1. have shown that in DU145 cells, which express wild-type PTEN, PKB/Akt phosphorylation on serine 473 is not detectable in the absence of serum (12) . In contrast, PKB/Akt phosphorylation on serine 473 is constitutively high in PTEN-null serum-starved PC3 cells (12) . As shown in Fig. 5 , which shows the effect of transfection of the various V 5 -tagged-ILK mutants on PKB/Akt serine 473 phosphorylation in PTEN-positive DU145 cells, transfection of wild-type ILK profoundly stimulates PKB/Akt-Ser-473 phosphorylation in the absence of serum. On the other hand, the S343A mutant fails to stimulate this phosphorylation, but S343D retains this ability and in fact may be more active than wild type ILK (Fig. 5A and Table II ). The importance of the PI(3,4,5)P 3 -binding region of ILK in regulating PKB phosphorylation is illustrated in Fig. 5B , since mutation of R211A abolishes the ability to stimulate PKB/Akt phosphorylation in the absence or presence of serum, strongly suggesting that phosphoinositide phospholipid binding to this region is critical. We have not yet tested this mutant for in vitro kinase activity. We wanted to determine whether the S343D mutation, mimicking the phosphorylated form of serine, would rescue the R211A mutation. In other words, we wanted to test whether the S343D mutation rendered ILK constitutively active and therefore insensitive to phosphoinositide phospholipid binding. As shown in Fig. 5B, S343D is unable to completely rescue the R211A mutation, indicating that both phosphoinositide phospholipid binding and Ser-343 phosphorylation are required to promote PKB/Akt phosphorylation in cells. This is further suggested by the finding that the ability of the S343D mutant to promote phosphorylation of PKB/Akt on serine 473 requires PI 3-kinase activity, since PI 3-kinase inhibitors, wortmannin and LY294002, inhibited (S343D) ILK-stimulated PKB/ Akt-Ser-473 phosphorylation (Fig. 6A ). In addition, the S343D ILK mutant is also sensitive to the ILK inhibitor KP-SD-1 (Fig.  6B) . Thus, the stimulation of serine 473 phosphorylation of PKB in serum-starved DU145 cells by both wild-type ILK and ILK (S343D) is completely inhibited by 100 M KP-SD-1.
It has been suggested by Lynch et al. (9) , that ILK promotes PKB/Akt serine 473 phosphorylation indirectly via an adapter function. This speculation was based on the atypical nature of the kinase domain of ILK, suggesting that ILK did not have sufficient activity to phosphorylate exogenous substrates, and on the observation that a mutant form of ILK (K220A), which behaved as a dominant negative by inhibiting constitutive phosphorylation of PKB/Akt-Ser-473 phosphorylation, could behave like the wild-type kinase by mutation of serine 343 to aspartic acid (S343D) (9) . We disagree with this speculation for the following reasons. First, ILK clearly has kinase activity against exogenous substrates as demonstrated previously by us (8, 12, 14, 16, 25) and in this paper (see Fig. 1 ) and independently by others (6, 15) . Second, as shown in Fig. 7 , the ILK mutant S343D is unable to reverse the potent dominant negative effect of the E359K mutation in its ability to suppress the constitutive PKB/Akt serine 473 phosphorylation found in serum-starved PTEN-null PC3 cells (Fig. 7) , again demonstrating the critical role of the kinase activity of ILK in promoting PKB/Akt serine 473 phosphorylation.
Collectively, these data demonstrate that ILK can promote PKB/Akt serine 473 phosphorylation directly and that the residues Ser-343 and Glu-359 are crucial to this activity. Furthermore, Arg-211 within the phosphoinositide phospholipid binding domain is also critical for ILK-mediated serine 473 phosphorylation of PKB/Akt. These data are summarized in Table II. ILK Interacts with PKB/Akt: Specific Role of Serine 343 of ILK-It has been proposed that PDK-1 may bind to the hydrophobic phosphorylation motif of PKB/Akt and block the phosphorylation of serine 473 at this site (20) . As shown above, ILK can phosphorylate PKB/Akt directly at this site in vitro (Figs. 1  and 2 ) and can promote phosphorylation of this site in intact cells (Fig. 5) . If PDK-1 indeed binds to PKB/Akt, then ILK would have to displace PDK-1 in order to phosphorylate serine 473 of PKB/Akt in vivo. We therefore examined whether ILK can interact with PKB/Akt and/or PDK-1, by carrying out co- 4 . Kinase activity of ILK is suppressed by mutation of Glu-359 to Lys and Ser-343 to Ala. Shown are ILK kinase assays, using GST fusion protein of ILK-WT, ILK (E359K), or ILK (S343A) prepared and purified from baculovirus as described under "Experimental Procedures." S6 substrate peptide was used as a substrate and [␥- immunoprecipitation/Western blot analysis of endogenous ILK, PKB, and PDK-1. As shown in Fig. 8A , anti-PKB and anti-PDK-1 antibodies can co-immunoprecipitate ILK from lysates of serum-starved and serum-containing DU145 cells, and the amount of ILK coimmunoprecipitated is higher in cells exposed to serum.
In order to identify the potential site on ILK responsible for these interactions, DU145 cells were transfected with V 5 epitope-tagged-ILK mutant constructs, lysed, and immunoprecipitated with anti-PKB antibody. As shown in Fig. 8B , Western blot analysis of the immunoprecipitates with anti-V 5 monoclonal antibody demonstrated that serine 343 of ILK is required for the interaction of ILK with PKB, since the S343A mutant failed to interact with PKB. Phosphorylation of Ser-343 is likely to be important in this interaction, since mutation of Ser-343 to Asp (S343D) did not have any effect on the interaction. Surprisingly, mutation of Arg-211 to Ala (R211A), which completely abolished the ability of ILK to promote phosphorylation of PKB at serine 473 in DU145 cells, had a minor effect on this interaction, as did inhibition of PI 3-kinase and ILK activity (Fig. 8B) . These results suggest that the primary role of Arg-211 of the phosphoinositide phospholipid binding motif is in the regulation of ILK activity rather than recruitment or co-localization of ILK to PKB. This is further supported by the fact that a myristoylated form of R211A ILK also failed to promote PKB/Akt phosphorylation (data not shown). In contrast, Ser-343 appears to play a major role in both catalytic function of ILK (Fig. 4) as well as in PKB recruitment (Fig. 8) .
We next wanted to determine whether the interaction of ILK with PKB would have any effect on the binding of PDK-1 to PKB/Akt. As shown in Fig. 9 , transfection of increasing amounts of wild-type ILK into DU145 cells resulted in a dosedependent inhibition of the interaction of PDK-1 with PKB/ /S343D) ). Transient transfection of the dominant negative-ILK (E359K) into PC3 cells, in which PKB-Ser-473 phosphorylation is constitutively elevated due to loss of PTEN (9), results in dramatic inhibition of phosphorylation in the presence and absence of serum. However, in contrast to previous reports (9), mutating serine 343 to an aspartic acid (S343D) in the background of dominant negative ILK (E359K) did not reverse its dominant negative characteristic. Akt, as determined by PDK-1/PKB co-immunoprecipitation. In agreement with the crucial role of serine 343 of ILK in the PKB/ILK interaction, the S343A mutant did not have any effect on PDK-1/PKB interaction (Fig. 9) . DISCUSSION PKB/Akt is a major downstream effector of growth factors, cytokines, and adhesion receptors in the regulation of cell survival (26, 27) . PKB/Akt is regulated by the second messenger product of PI 3-kinase action, PI(3,4,5)P 3 , by direct binding to the pleckstrin homology domain of PKB/Akt and by the activation of upstream phosphoinositide PDKs, which phosphorylate threonine 308 and serine 473 residues required for its full activation. PKB/Akt is constitutively activated in PTEN-null or mutant cells (12) , suggesting that a major target of the tumor suppressor effect of PTEN is PKB/Akt. The kinase responsible for phosphorylating PKB/Akt on threonine 308 has been identified as PDK-1, and although a separate kinase, PDK-2, was originally implicated in phosphorylating the hydrophobic site serine 473, it has recently been suggested that this site may be subject to autophosphorylation (21, 28) . The current model for PKB/Akt activation proposes that upon plasma membrane recruitment of PKB/Akt via the pleckstrin homology domain, the enzyme undergoes a conformational change allowing for binding of PDK-1 and phosphorylation of threonine 308. Phosphorylation of this site stimulates autophosphorylation activity of PKB/Akt. PDK-1 has also been implicated in the regulation of phosphorylation of serine 473 by binding to this hydrophobic site and preventing its phosphorylation. Upon an appropriate signal, PDK-1 is displaced by a PIF, generated from PRK-2 (18, 20, 29) , allowing for autophosphorylation to take place at this site (18) . Although activity of PIF peptide has been demonstrated in vitro, it is not clear whether a physiological form of PIF exists in cells.
The phosphorylation of serine 473 of PKB/Akt is highly inducible by upstream signals, whereas threonine 308 phosphorylation is largely constitutive (26, 30) . For this reason, activation of PKB/Akt is almost always evaluated by analyzing the phosphorylation state of serine 473 using phosphospecific antibodies.
ILK fulfills many of the properties of an upstream regulator of phosphorylation of PKB/Akt on serine 473. ILK activity is stimulated by both cell adhesion to extracellular matrix and by growth factors in a PI 3-kinase-dependent manner (8, 9, 11, 12, 25) , and this activity of ILK is stimulated in vitro in the presence of PI(3,4,5)P 3 (8) . Furthermore, ILK activity is inhibited by PTEN (11, 12) . ILK is also a potent suppressor of anoikis, a function which is dependent on its ability to activate PKB/Akt (10) . Utilizing transfection studies with wild-type and dominant negative forms of ILK, it has been demonstrated that ILK can regulate serine 473 phosphorylation but not threonine 308 phosphorylation of PKB/Akt (8, 9, 12) . However, whether ILK phosphorylates PKB/Akt at this site directly, or whether it functions as an adapter molecule has been debated (8, 9) , based on the speculation that ILK may lack kinase activity or possess weak kinase activity because of the atypical nature of portions of its kinase domain (14, 16) .
We have previously shown that recombinant ILK can phosphorylate PKB/Akt on serine 473 in vitro (8) . In order to acquire stronger evidence for the possible role of ILK in the direct phosphorylation of PKB/Akt, we took an unbiased approach of a biochemical purification of kinase activity responsible for phosphorylation of PKB/Akt from tissue extracts. A similar approach has recently been used in the identification of ILK also as a Ca 2ϩ -independent myosin light chain kinase (16) , work that has proven that ILK is indeed a bona fide serine/ threonine protein kinase.
We have demonstrated here that this unbiased purification of PKB-kinase activity using an in-gel kinase assay coupled with MALDI-TOF mass spectrometry resulted in the identifi- cation of ILK as a PKB kinase. We have further demonstrated using serine 473 phosphospecific antibodies and a highly selective small molecule ILK inhibitor that this phosphorylation is on serine 473.
We also carried out mutational analysis of ILK and have identified arginine 211, which is located in the PI(3,4,5)P 3 binding region, and serine 343, within the activation loop of ILK (9), as critical residues for the stimulation of PKB/Akt phosphorylation by ILK in intact cells. We also provide novel data demonstrating that ILK can complex with both PKB and PDK-1 and that the serine 343 residue is critical for ILK/PKB interaction. Autophosphorylation of serine 343 has been proposed to be required for the stimulation of PKB/Akt serine 473 phosphorylation by ILK (9) . Our data further suggest a role of phosphorylation at this site, since mutation of Ser 343 to Ala inhibited both stimulation of phosphorylation of PKB/Akt and interaction with it, whereas mutation of Ser 343 to aspartic acid (S343D) had no effect. In addition, we have shown that wildtype ILK can disrupt endogenous PKB/PDK-1 interaction, whereas the S343A mutant of ILK cannot. It is possible that the primary interaction of ILK is with PDK-1, since the critical serine residue in ILK, serine 343, implicated in the interaction resides in a hydrophobic site, Val-Lys-Phe-Ser*-Phe-Glu, resembling the PIF consensus, X-X-Phe-Asp-Tyr (20) . Our finding that substitution of the serine 343 with alanine fails to disrupt PKB/PDK-1 interaction and fails to stimulate PKB/Akt serine 473 phosphorylation whereas substitution with aspartic acid behaves similarly to wild-type ILK further suggests that Ser-343-phosphorylated ILK may bind PDK-1 in an analogous manner to PIF (which contains an aspartic acid at the analogous site) and displaces it from PKB/Akt.
The combination of novel data presented in this paper and previously published data allows us to formulate an alternative model for the phosphorylation of serine 473 of PKB/Akt. This model, depicted in Fig. 10 , implicates ILK as a major upstream regulator of PKB/Akt. The role of ILK appears to be in its ability to bind to PKB/Akt and/or PDK-1 and disrupt their interaction. This would effectively unmask the hydrophobic serine 473 site, which ILK can phosphorylate directly. In addition to the promotion of direct phosphorylation of serine 473 by ILK, the displacement of PDK-1 from PKB caused by ILK would also allow PKB/Akt to autophosphorylate at this site (21) . The extent to which activation of PKB/Akt depends on the phosphorylation of serine 473 by ILK versus autophosphorylation is not clear as yet, although inhibition of ILK in cells results in an almost complete inhibition of PKB/Akt serine 473 phosphorylation. It is entirely possible that the role of ILK versus autophosphorylation is also regulated by higher order scaffolds. In this regard, the interactions of ILK with actin cytoskeletal linkers such as paxillin (31, 32) and actopaxin (32) and adapter proteins such as PINCH (33) could be involved in such regulation. FIG. 10 . Schematic representation of the phosphorylation of PKB-Ser-473. Shown is our proposed model for the phosphorylation of serine 473 of PKB by the integrin-linked kinase, ILK, whereby PDK-1 phosphorylates PKB at Thr-308 and binds to PKB such that it blocks the hydrophobic serine 473 site. ILK is able to displace the bound PDK-1 and promote the phosphorylation of PKB at serine 473.
